13 citations · 29 across the 18 of their papers we have counts for
4 papers · 1 filter
Multi-outcome trials with a generalised number of efficacious outcomes
Martin Law, Michael J. Grayling, Adrian P. Mander
Existing multi-outcome designs focus almost entirely on evaluating whether all outcomes show evidence of efficacy or whether at least one outcome shows evidence of efficacy. While…
Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials
Kevin Kunzmann, Michael J. Grayling, Kim M. Lee +3
Adapting the final sample size of a trial to the evidence accruing during the trial is a natural way to address planning uncertainty. Designs with adaptive sample size need to acco…
Two-stage single-arm trials are rarely reported adequately
Michael J. Grayling, Adrian P. Mander
Purpose: Two-stage single-arm trial designs are commonly used in phase II oncology to infer treatment effects for a binary primary outcome (e.g., tumour response). It is imperative…
A review of Bayesian perspectives on sample size derivation for confirmatory trials
Kevin Kunzmann, Michael J. Grayling, Kim May Lee +3
Sample size derivation is a crucial element of the planning phase of any confirmatory trial. A sample size is typically derived based on constraints on the maximal acceptable type…